Indeed, advances have been made in developing erbB3-targeted therapy [86], and several anti-erbB3 monoclonal Abs exhibit efficacy in vivo and show promise as novel cancer therapeutics [87,88]. The gene discussed is ERBB3; the disease is cancer.